Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

NCT04801797 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

172

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Cytarabine
DRUG: Idarubicin
DRUG: Daunorubicin
DRUG: Liposomal daunorubicin and cytarabine
DRUG: Venetoclax
DRUG: Azacitidine

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]